推荐用于II期的ALT-803剂量是20ug/kg 每周1次皮下注射,联合纳武单抗240mg 每两周1次静脉滴注。 Haalthy语 ALT-803目前正在美国开展ALT-803联合纳武单抗治疗经治晚期非小细胞肺癌的II期临床试验招募,登记号NCT02523469。 另据报道,早在2014年AltorBioScience公司向深圳北科生物转让ALT-803生产技术,但目前未见国内临床...
To test this, we performed a first-in-human multi-center phase 1 trial (ClinicalTrials.gov NCT01885897 ) of the IL-15 superagonist complex ALT-803 in patients who relapsed >60 days after allo-HCT. ALT-803 was administered to 33 patients via the intravenous (IV) or subcutaneous (SQ) ...
ALT-803 is an IL-15 superagonist complex that has been developed as a potent antitumor immunotherapeutic agent and is in clinical trials. Here we describe the creation of a novel fusion molecule, 2B8T2M, using the ALT-803 scaffold fused to four single chains of the tumor-targeting monoclonal...
Randomized trial of behavior therapy for adults with Tourette syndrome. Archives of General Psychiatry , 69 (8), 795–803. CentralWilhelm S, Peterson AL, Piacentini J, Woods DW, Deckersbach T, Sukhodolsky DG, Chang S, Liu H, Dziura J, Walkup JT, Scahill L. Ra...